| The incidence of chronic kidney disease is increasing year by year all over the world, and resulting in gradual increase of the amount of patient with chronic renal failure. Rapid growth in the number of patient with CRF brings about a sharp increase of medical expenses, which is a heavy financial burden to countries and families. Since1970s, modern treatments such as the dialysis therapy and the renal transplantation have had rapid developments, so the treatment effect of CRF has also been improved significantly. But the most of patients ccould not bear the higher cost and multifold untoward reaction, so the non-dialysis therapy is still believed as the more acceptable method that plays an important role in the treatment on chronic renal failure.ObjectiveThe chronic renal failure, a common obstinate disease clinically, is the ultimate outcome of multiple renal diseases. The combination of traditional Chinese medicine and modern medicine plays a certain role in treatment on chronic renal failure, particularly in improving the clinical symptom, increasing creatinine clearance rate, and in reducing blood creatinine and blood urea nitrogen. Therefore the further study on the drug therapy for chronic renal failure, including the application of traditional Chinese medicine, has significant meaning for treating chronic renal insufficiency and delaying the development of disease progress. To observe clinical characteristic of CRF, this study investigates clinical curative effect of the combinative treatment with Alprostadil and Shenkang Injection on the chronic renal failure. We hope to search a better method to control and cure the process of Chronic Renal Failure, and provide basis for further study on mechanism of chronic renal failure.MethodWe collected86patients with chronic renal failure who were in hospital from the October,2010to the August,2011. All patients were diagnosed according to the diagnostic criteria of chronic renal failure.86cases of CRF patients were randomly divided into two groups:(1) In control group (43patients), the men were28cases and the women were15cases. The mean age was (43.6±9.1) years, and the average course of disease was (3.8±1.5) years.(2) In treatment group (43patients), the men were23cases and the women were20cases. The mean age was (42.6±9.2) years, and the average course of disease was (3.9±1.3) years.86patients included49patients with chronic glomerulonephritis,23patients with diabetic nephropathy and14patients with hypertension damage of kidney. Both groups were treated with the routine therapy (including diet and symptomatic treatment). The control group was adminstrated with ligustrazine200mg in250ml5%Glucose, once a day medication for14days. The treatment group was adminstrated with alprostadil injection20μg in100ml physiological saline, and Shenkang injection in300ml5%Glucose, intravenous injection, once a day medication for14days. Contrast the concentration of the serum creatinine (Scr), creatinine clearance rate (Ccr), blood urea nitrogen(BUN),24-hour urinary protein(Upro), triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1(Apo-A1), apolipoprotein B100(Apo-B100), arylesterase(ArE)and high sensitive C reactive protein(hs-CRP) before and after the treatment, and observe and record the change of clinical symptoms and physical signs. After14days with parallel treatment, we observed the curative effects and made evaluation of therapeutic efficiency.Result 1. Comparison of results before and after treatment in both groups:In cases of treatment group, the Scr, BUN, UPro, TC, Apo-B100, and hs-CRPC(P<0.05) were significantly decreased after treatment, and the Ccr, ArE, HDL-C, and Apo-A1were increased (P<0.05) contrasting before. In cases of control group, the Ccr, Scr, BUN, TC, HDL-C, Apo-B100, ArE, and hs-CRP were improved (P<0.05) contrasting before. Therefore the difference has meaning of statistics.2. Comparison of results before and after treatment in both groups:Before treatment, there were no statistical differences between the treatment group and the control group in clinical symptoms, physical signs and biomedical indexes (P>0.05). After treatment, there were significant difference between the treatment group and the control group in these indexes (P<0.05).3. The result of drug safety index:Before and after treatment, there was no difference in drug safety indexes, such as liver function, blood presure and weight (P>0.05). The two drugs have good safety, and record of untoward reaction is not find in duration of treatment.ConclusionThe combination treatment of alprostadil and shenkang injection can not only improve renal function but also make multiple pathogenic factors better, such as disturbance of lipid metabolism. The combination of Chinese and Western medicine is superior to the treatment which only use western medicine or the Chinese medicine, and there are few adverse effects with combinative treatment. |
PDF Full Text Request